Comparing the efficacy of stimulants for ADHD in children and adolescents using meta-analysis
The DOI matches its Crossref record; 54 of the 54 references it cites were found in a registry or an index.
Abstract
Stimulants used to treat attention-deficit/hyperactivity disorder (ADHD) have been well researched, but comparisons among stimulants are hindered by the absence of direct comparative trials. The goal of this work was to compare the efficacy of methylphenidate and amfetamine formulations through a meta-analysis of double-blind placebo-controlled trials. We analyzed recent published literature on the stimulant therapy of ADHD to describe the variability of drug-placebo effect sizes. A literature search was conducted to identify double-blind, placebo-controlled studies of ADHD in children and adolescents published after 1979. Meta-analysis regression assessed the influence of medication type and study design features on medication effects. Twenty-three trials met criteria and were included in this meta-analysis. These trials studied 11 drugs using 19 different outcome measures of hyperactive, inattentive, or impulsive behavior. We found significant differences between amfetamine and methylphenidate products, even after correcting for study design features that might have confounded the results. Our analyses indicate that effect sizes for amfetamine products are significantly, albeit moderately, greater than those for methylphenidate. We found that most measures of effect from all studies were statistically significant. Our findings suggest that amfetamine products may be moderately more efficacious than methylphenidate products, even after controlling for potentially confounding…
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Meta-analyses have demonstrated that stimulant and non-stimulant medications for ADHD effectively reduce ADHD symptoms inchildren and adults 142,143 .”
From Attention-deficit/hyperactivity disorder (2015) · cites this paper as [143]
In the citing paper
“some patients preferentially respond to and tolerate one or the other 143 .”
From Attention-deficit/hyperactivity disorder (2015) · cites this paper as [143]
In the citing paper
“Although the efficacy of both classes of stimulants is similar”
From Attention-deficit/hyperactivity disorder (2015) · cites this paper as [143]
In the citing paper
“It has been speculated that the moderately greater efficacy of AMP-based agents compared with MPH-based agents in ADHD may be related to differences in their molecular actions (33), but to date there is no conclusive clinical evidence to support this speculation.”
In the citing paper
“It is noteworthy that medications for ADHD operate by altering the availability of NE and DA at cortical sites (Faraone and Buitelaar, 2010),”
From Is autonomic nervous system function atypical in Attention Deficit Hyperactivity Disorder (ADHD)? A systematic review of the evidence (2020) · cites this paper as Faraone and Buitelaar, 2010
2 more claims about this paper
Create a free account to see every claim other papers make about this one.
Citations
Cites
Statistical Power Analysis for the Behavioral Sciences
Muller, K. (1989) · Technometrics · doi:10.1080/00401706.1989.10488618 · Cited by 99,167
Statistical power analysis for the behavioral sciences
(1990) · Computers, Environment and Urban Systems · doi:10.1016/0198-9715(90)90050-4 · Cited by 65,269
Measuring inconsistency in meta-analyses
Higgins, J. P. T., Thompson, S. G., Deeks, J. J., & Altman, D. G. (2003) · BMJ · doi:10.1136/bmj.327.7414.557 · Cited by 63,139
Bias in meta-analysis detected by a simple, graphical test
Egger, M., Smith, G. D., Schneider, M., & Minder, C. (1997) · BMJ · doi:10.1136/bmj.315.7109.629 · Cited by 56,722
Meta-analysis in clinical trials
DerSimonian, R., & Laird, N. (1986) · Controlled Clinical Trials · doi:10.1016/0197-2456(86)90046-2 · Cited by 39,552 · cited 1×
“Our meta-analysis used the random effects model of DerSimonian and Laird [ 8 ].”
MethodThe meaning and use of the area under a receiver operating characteristic (ROC) curve.
Hanley, J. A., & McNeil, B. J. (1982) · Radiology · doi:10.1148/radiology.143.1.7063747 · Cited by 21,856
Statistical Methods for Meta-Analysis
Wasserman, S., Hedges, L. V., & Olkin, I. (1988) · Journal of Educational Statistics · doi:10.2307/1164953 · Cited by 10,326
Methods of Meta-Analysis: Correcting Error and Bias in Research Findings
Schmidt, F. L., & Hunter, J. E. (2015) · doi:10.4135/9781483398105 · Cited by 5,542
Statistical Methods for Meta-Analysis.
Freeman, P. R., Hedges, L. V., & Olkin, I. (1986) · Biometrics · doi:10.2307/2531069 · Cited by 4,784
(1967) · Project Euclid (Cornell University) · Cited by 4,720
Research works printed but not linked: 1
- Faraone SV, Sergeant J, Gillberg C, Biederman J (2003) The worldwide prevalence of ADHD: is it an American condition? World Psychiatry 2:104–113
Cited by
Items 101–200 of 485
Treceño, C., Martín Arias, L. H., Sáinz, M., Salado, I., García Ortega, P., Velasco, V., Jimeno, N., Escudero, A., Velasco, A., & Carvajal, A. (2012) · Pharmacoepidemiology and Drug Safety · doi:10.1002/pds.2348 · Cited by 54
Geissler, J., & Lesch, K.-P. (2011) · Expert Review of Neurotherapeutics · doi:10.1586/ern.11.136 · Cited by 53
Neurocognitive Predictors of ADHD Outcome: a 6-Year Follow-up Study
van Lieshout, M., Luman, M., Twisk, J. W. R., Faraone, S. V., Heslenfeld, D. J., Hartman, C. A., Hoekstra, P. J., Franke, B., Buitelaar, J. K., Rommelse, N. N. J., et al. (2017) · Journal of Abnormal Child Psychology · doi:10.1007/s10802-016-0175-3 · Cited by 54
“This may be of importance, as pharmacological treatment may impact on outcomes; for example, in a meta-analysis including 23 studies, it was found that both amphetamine and methylphenidate products were efficacious in treating ADHD symptoms (Faraone and Buitelaar 2010).”
BackgroundSelf-citationGeladé, K., Janssen, T. W. P., Bink, M., Twisk, J. W. R., van Mourik, R., Maras, A., & Oosterlaan, J. (2017) · European Child & Adolescent Psychiatry · doi:10.1007/s00787-017-1072-1 · Cited by 66
“Stimulant medication is effective and frequently used as a treatment for behavioral [6] and neurocognitive [7] impairments found in ADHD.”
BackgroundDeficiency of tumor suppressor NDRG2 leads to attention deficit and hyperactive behavior
Li, Y., Yin, A., Sun, X., Zhang, M., Zhang, J., Wang, P., Xie, R., Li, W., Fan, Z., Zhu, Y., et al. (2017) · Journal of Clinical Investigation · doi:10.1172/jci94455 · Cited by 55
“Canonical ADHD-associated hyperactivity should be alleviated by methylphenidate, a psychostimulant that increases dopamine release and is routinely used to treat ADHD (32, 33).”
BackgroundJang, B., Song, J., Kim, J., Kim, S., Lee, J.-Y., Shin, H.-Y., Kwon, J., Kim, Y., & Joung, Y. (2015) · The Journal of Alternative and Complementary Medicine · doi:10.1089/acm.2015.0067 · Cited by 76
Marraccini, M. E., Weyandt, L. L., Rossi, J. S., & Guðmundsdóttir, B. G. (2016) · Experimental and Clinical Psychopharmacology · doi:10.1037/pha0000079 · Cited by 58
“…stimulant medications for the reduction of Attention- Deficit/Hyperactivity Disorder (ADHD) symptomatology among adults and children has been well documented through clinical trials and meta-analyses (Faraone, 2012; Faraone & Biederman, 2002; Faraone & Buitelaar, 2010; Faraone and Glatt, 2010).”
Linton, D., Barr, A. M., Honer, W. G., & Procyshyn, R. M. (2013) · Current Psychiatry Reports · doi:10.1007/s11920-013-0355-6 · Cited by 56
“Despite some suggestions that stimulants may be over-prescribed, they are nonetheless highly effective [14] and well tolerated [15] for the treatment of ADHD.”
BackgroundADHD pharmacogenetics across the life cycle: New findings and perspectives
Bruxel, E. M., Akutagava‐Martins, G. C., Salatino‐Oliveira, A., Contini, V., Kieling, C., Hutz, M. H., & Rohde, L. A. (2014) · American Journal of Medical Genetics Part B: Neuropsychiatric Genetics · doi:10.1002/ajmg.b.32240 · Cited by 51
“All of them determine good response in decreasing ADHD symptoms, although their pharmacokinetics are quite different [Faraone and Buitelaar, 2010].”
BackgroundAn Update on Medication Management of Behavioral Disorders in Autism
Baribeau, D. A., & Anagnostou, E. A. (2014) · Current Psychiatry Reports · doi:10.1007/s11920-014-0437-0 · Cited by 62
How do stimulant treatments for ADHD work? Evidence for mediation by improved cognition
Hawk, L. W., Fosco, W. D., Colder, C. R., Waxmonsky, J. G., Pelham, W. E., & Rosch, K. S. (2018) · Journal of Child Psychology and Psychiatry · doi:10.1111/jcpp.12917 · Cited by 51
“There is strong evidence that stimulants reduce parent- and teacher-reported ADHD symptoms (Faraone & Buitelaar, 2010; MTA Cooperative Group, 1999) and improve classroom behavior (Pelham et al., 2014; Prasad et al., 2013), including increasing on-task behavior and the amount of school work…”
Solanto, M. V., & Scheres, A. (2020) · Journal of Attention Disorders · doi:10.1177/1087054720951865 · Cited by 71
“…active treatment against a supportive condition to control for non-specific effects of therapy (Safren et al., 2010; Solanto et al., 2010) have yielded effect sizes greater than 0.70 for both programs, which is comparable to the effect size for long-acting stimulants (Faraone & Buitelaar, 2010).”
ResultInfluentialBiederman, J., Fried, R., Tarko, L., Surman, C., Spencer, T., Pope, A., Grossman, R., McDermott, K., Woodworth, K. Y., & Faraone, S. V. (2017) · Journal of Attention Disorders · doi:10.1177/1087054714538656 · Cited by 50
“Whereas stimulants remain the mainstay of treatment for ADHD due to their large effect sizes (Alliance, 2008; Faraone, 2012; Faraone & Buitelaar, 2010; Faraone & Glatt, 2010; Kooij et al., 2004), their effects on EF deficits (EFDs) are more ambivalent and generally more modest.”
BackgroundSelf-citationNewcorn, J. H., Nagy, P., Childress, A. C., Frick, G., Yan, B., & Pliszka, S. (2017) · CNS Drugs · doi:10.1007/s40263-017-0468-2 · Cited by 50
“A metaanalysis [6] that included studies of C 2 weeks in duration found that amphetamine and methylphenidate were superior to placebo in children and adolescents with ADHD, with amphetamine having somewhat larger ESs.”
BackgroundLeffa, D. T., Panzenhagen, A. C., Salvi, A. A., Bau, C. H. D., Pires, G. N., Torres, I. L. D. S., Rohde, L. A., Rovaris, D. L., & Grevet, E. H. (2019) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2019.02.019 · Cited by 54
“Clinical studies have been able to demonstrate positive effects of MPH on the symptomatological dimensions of ADHD (Catala-Lopez et al., 2017; Faraone and Buitelaar, 2010; Faraone and Glatt, 2010; Storebo et al., 2015), diminishing inattention, hyperactivity/impulsivity symptoms (Huss et al., 2014;…”
BackgroundDöpfner, M., Hautmann, C., Dose, C., Banaschewski, T., Becker, K., Brandeis, D., Holtmann, M., Jans, T., Jenkner, C., Millenet, S., et al. (2017) · BMC Psychiatry · doi:10.1186/s12888-017-1433-9 · Cited by 49
“Meta-analyses indicate that the effect sizes of atomoxetine and other non-stimulant medications are significantly smaller than those of immediaterelease stimulants or long-acting stimulants [4, 5].”
BackgroundCatalá-López, F., Hutton, B., Núñez-Beltrán, A., Mayhew, A. D., Page, M. J., Ridao, M., Tobías, A., Catalá, M. A., Tabarés-Seisdedos, R., & Moher, D. (2015) · Systematic Reviews · doi:10.1186/s13643-015-0005-7 · Cited by 51
“Some reviews were focused on one particular treatment approach only [33-40], most often medications; while others compared medications and”
BackgroundMethodWigal, S. B., Childress, A. C., Belden, H. W., & Berry, S. A. (2013) · Journal of Child and Adolescent Psychopharmacology · doi:10.1089/cap.2012.0073 · Cited by 49
“…the SKAMP-combined score at 4 hours post-dose, was statistically significantly lower with NWP06 treatment compared with placebo treatment, and the large effect size observed (2.5) is in line with effect sizes observed for other stimulants in the treatment of ADHD (Faraone and Buitelaar 2010).”
ResultInfluentialMixed Emotions: An Incentive Motivational Model of Sexual Deviance
Smid, W., & Wever, E. C. (2018) · Sexual Abuse · doi:10.1177/1079063218775972 · Cited by 58
Behavioral effects of neurofeedback in adolescents with ADHD: a randomized controlled trial
Bink, M., van Nieuwenhuizen, C., Popma, A., Bongers, I. L., & Boxtel, G. J. M. V. (2014) · European Child & Adolescent Psychiatry · doi:10.1007/s00787-014-0655-3 · Cited by 53
“Stimulant medication is effective in reducing ADHD symptoms [9] in 70–80 % of the children suffering from ADHD [10], and in almost half of the children with ASD and comorbid ADHD [11].”
BackgroundTargeting Functional Impairments in the Treatment of Children and Adolescents with ADHD
Sasser, T. R., Schoenfelder, E. N., & Stein, M. A. (2016) · CNS Drugs · doi:10.1007/s40263-016-0400-1 · Cited by 57
“Although numerous randomized controlled trials have demonstrated the robust short-term efficacy of stimulant and non-stimulant medications in reducing ADHD symptomatology [6, 7], improvements in symptoms do not necessarily yield improvements in functioning [8–11].”
Lepelletier, F.-X., Tauber, C., Nicolas, C., Solinas, M., Castelnau, P., Belzung, C., Emond, P., Cortese, S., Faraone, S. V., Chalon, S., et al. (2015) · The International Journal of Neuropsychopharmacology · doi:10.1093/ijnp/pyu044 · Cited by 50
“Because MPH has a favorable efficacy/ tolerance ratio (Faraone and Buitelaar, 2010), it has been used in children but also in adults with ADHD over the recent years (Banaschewski et al., 2006).”
MethodSelf-citationCook, N. E., Huang, D. S., Silverberg, N. D., Brooks, B. L., Maxwell, B., ZAFONTE, R. D., Berkner, P. D., & Iverson, G. L. (2017) · The Clinical Neuropsychologist · doi:10.1080/13854046.2017.1317031 · Cited by 49
Psychosocial Interventions in Attention-Deficit/Hyperactivity Disorder
Antshel, K. M. (2014) · Child and Adolescent Psychiatric Clinics of North America · doi:10.1016/j.chc.2014.08.002 · Cited by 73
Gordon, H. A., Rucklidge, J. J., Blampied, N. M., & Johnstone, J. M. (2015) · Journal of Child and Adolescent Psychopharmacology · doi:10.1089/cap.2015.0105 · Cited by 45
“They are also substantially larger than those typically reported for placebo effects (Grissom 1996) and at least comparable to the most recent meta-analyses examining the effects of stimulant medication on ADHD, which found medium to large effect sizes (Faraone 2009; Faraone and Buitelaar 2010).”
ResultAttention-deficit/hyperactivity disorder in postsecondary students
Murkett, K., Smart, W., & Nugent, K. (2014) · Neuropsychiatric Disease and Treatment · doi:10.2147/ndt.s64136 · Cited by 67
“In a separate metaanalysis of 23 studies of amphetamine and methylphenidate products in children and adolescents with ADHD, effect sizes for amphetamine products were significantly greater than those for methylphenidate.(74) High variability among the”
ResultCatecholaminergic modulation of the avoidance of cognitive control.
Froböse, M. I., Swart, J. C., Cook, J. L., Geurts, D. E. M., den Ouden, H. E. M., & Cools, R. (2018) · Journal of Experimental Psychology General · doi:10.1037/xge0000523 · Cited by 54
“In ADHD, for example, MPH is usually the first-line medication and is generally found to remedy cognitive deficits (Coghill et al., 2013; Faraone & Buitelaar, 2010; Leonard, Mccartan, White, & King, 2004), such as higher trait impulsivity have been shown to exhibit greater beneficial effects of…”
Faraone, S. V., McBurnett, K., Sallee, F. R., Steeber, J., & López, F. A. (2013) · Clinical Therapeutics · doi:10.1016/j.clinthera.2013.09.005 · Cited by 44
Self-citationPharmacotherapy in autism spectrum disorders, including promising older drugs warranting trials
Hellings, J. A. (2023) · World Journal of Psychiatry · doi:10.5498/wjp.v13.i6.262 · Cited by 52
Soutullo, C., Banaschewski, T., Lecendreux, M., Johnson, M., Zuddas, A., Anderson, C., Civil, R., Higgins, N., Bloomfield, R., Squires, L. A., et al. (2013) · CNS Drugs · doi:10.1007/s40263-013-0086-6 · Cited by 44
“rect evidence that stimulants based on amfetamine may have slightly greater efficacy than those based on methylphenidate in reducing symptoms of ADHD in children and adolescents [1].”
BackgroundPliszka, S. R., Wilens, T. E., Bostrom, S., Arnold, V. K., Marraffino, A., Cutler, A. J., López, F. A., DeSousa, N. J., Sallee, F. R., Incledon, B., et al. (2017) · Journal of Child and Adolescent Psychopharmacology · doi:10.1089/cap.2017.0084 · Cited by 44
“2017), clinical trials of stimulant-treated children with ADHD have primarily focused on improving symptoms during the school day and after-school homework time (Faraone and Buitelaar 2010; Coghill et al. 2013; Maldonado 2013; Storebø et al. 2015).”
BackgroundChen, C., Yeh, H.-H. H., Chen, K.-H., Chang, I., Wu, E. C., & Lin, K. (2011) · Journal of Child and Adolescent Psychopharmacology · doi:10.1089/cap.2010.0107 · Cited by 46
“…methylphenidate (MPH) treatment, a meta-analysis study found that the effect sizes on both hyperactivity-impulsivity and inattention fell between 0.5 and 1.5 (Faraone and Buitelaar 2010); the effect size has also been reported to be less salient in pre-school children (Greenhill et al .”
InfluentialSchei, J., Nøvik, T. S., Thomsen, P. H., Indredavik, M. S., & Jozefiak, T. (2015) · BMC Psychiatry · doi:10.1186/s12888-015-0491-0 · Cited by 56
“For children and adolescents with ADHD, medical treatment is one of the major options to decrease ADHD symptoms and improve psychosocial functioning and QoL [25,28-30].”
BackgroundRoskell, N. S., Setyawan, J., Zimovetz, E. A., & Hodgkins, P. (2014) · Current Medical Research and Opinion · doi:10.1185/03007995.2014.904772 · Cited by 42
Is neurofeedback effective in children with ADHD? A systematic review and meta-analysis
Rahmani, E., Mahvelati, A., Alizadeh, A., Mokhayeri, Y., Rahmani, M., Zarabi, H., & Hassanvandi, S. (2022) · Neurocase · doi:10.1080/13554794.2022.2027456 · Cited by 54
Attention deficit hyperactivity disorder
Antshel, K. M., & Barkley, R. A. (2020) · Handbook of clinical neurology · doi:10.1016/b978-0-444-64148-9.00003-x · Cited by 59
Leffa, D. T., Bellaver, B., Salvi, A. A., de Oliveira, C., Caumo, W., Grevet, E. H., Fregni, F., Quincozes‐Santos, A., Rohde, L. A., & Torres, I. L. D. S. (2018) · Brain stimulation · doi:10.1016/j.brs.2018.04.001 · Cited by 50
Faraone, S. V., Po, M. D., Komolova, M., & Cortese, S. (2019) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.18r12210 · Cited by 56
“To address these clinical needs and research gaps, we conducted a systematic review with meta-analysis of RCTs of methylphenidate reporting sleep-related AEs, with the aims to (1) determine the study design–related confounders that significantly impact the relative risk (RR), (2) determine the magnitude of the pooled…”
BackgroundMethodInfluentialSelf-citationWang, C. H., Mazursky-Horowitz, H., & Chronis-Tuscano, A. (2014) · Current Psychiatry Reports · doi:10.1007/s11920-014-0474-8 · Cited by 39
Grünblatt, E., Werling, A. M., Roth, A., Romanos, M., & Walitza, S. (2019) · Journal of Neural Transmission · doi:10.1007/s00702-019-01998-x · Cited by 39
Frölich, J., Banaschewski, T., Döpfner, M., & Görtz‐Dorten, A. (2014) · Expert Opinion on Drug Metabolism & Toxicology · doi:10.1517/17425255.2014.922542 · Cited by 42
“2 Clinical and neuropsychological effects Robust clinical effects of psychostimulants, mainly MPH, in the treatment of children and adolescents with ADHD have been demonstrated in large placebo-controlled studies [4,85].”
BackgroundAge-dependent, lasting effects of methylphenidate on the GABAergic system of ADHD patients
Solleveld, M. M., Schrantee, A., Puts, N. A. J., Reneman, L., & Lucassen, P. J. (2017) · NeuroImage: Clinical · doi:10.1016/j.nicl.2017.06.003 · Cited by 39
Moore, D. A., Richardson, M. A., Gwernan‐Jones, R., Coon, J. T., Stein, K., Rogers, M., Garside, R., Logan, S., & Ford, T. J. (2015) · Journal of Attention Disorders · doi:10.1177/1087054715573994 · Cited by 60
“…interventions for ADHD in school settings: An overarching synthesis of systematic reviews The effectiveness of ADHD medication is well established (Faraone & Buitelaar, 2010); however, drug treatment may be declined or poorly tolerated, there is low long-term compliance and not all young people…”
BackgroundPossible role of a dysregulation of the endogenous opioid system in antisocial personality disorder
Bandelow, B., & Wedekind, D. (2015) · Human Psychopharmacology Clinical and Experimental · doi:10.1002/hup.2497 · Cited by 41
“These stimulants act on different neurotransmitter systems but have in common that they all act also on the EOS (de Wit et al., 2002; Pietras et al., 2003; Creighton et al., 2004; Faraone and Buitelaar, 2010).”
BackgroundSkoglund, C. B., Brandt, L., D'Onofrio, B. M., Larsson, H., & Franck, J. (2017) · European Neuropsychopharmacology · doi:10.1016/j.euroneuro.2017.08.435 · Cited by 44
“It is well established that pharmacological treatment of ADHD using stimulant medication improves ADHD core symptoms (Faraone and Buitelaar, 2010, Faraone and Glatt, 2010).”
BackgroundHiscock, H., Mulraney, M., Efron, D., Freed, G., Coghill, D., Sciberras, E., Warren, H., & Sawyer, M. (2020) · Australian Journal of Psychology · doi:10.1111/ajpy.12256 · Cited by 34
ADHD: Overdiagnosed and overtreated, or misdiagnosed and mistreated?
Manos, M. J., Giuliano, K., & Geyer, E. (2017) · Cleveland Clinic Journal of Medicine · doi:10.3949/ccjm.84a.15051 · Cited by 50
Placebo effect in child and adolescent psychiatric trials
Parellada, M., Moreno, C., Moreno, M., Espliego, A., Portugal, E., & Arango, C. (2011) · European Neuropsychopharmacology · doi:10.1016/j.euroneuro.2011.09.007 · Cited by 41
“…there are significant differences between different stimulants , effect sizes for stimulants in children and adolescents with ADHD are around 1.2 and the number needed to treat (NNT) range between 2 and 2.6, figures hardly ever seen in adult neuropsychopharmacology (Faraone and Buitelaar, 2010).”
InfluentialConnolly, J. J., Glessner, J., Kao, C., Elia, J., & Hakonarson, H. H. (2015) · Therapeutic Innovation & Regulatory Science · doi:10.1177/2168479015599811 · Cited by 47
Besag, F., Gobbi, G., Caplan, R., Sillanpää, M. L., Aldenkamp, A. P., & Dunn, D. W. (2016) · Epileptic Disorders · doi:10.1684/epd.2016.0811 · Cited by 46
Chan, S. K. C., Zhang, D., Bögels, S. M., Chan, C. S., Lai, K. Y. C., Lo, H. H. M., Yip, B. H. K., Lau, E. N. S., Gao, T. T., & Wong, S. Y. S. (2018) · BMJ Open · doi:10.1136/bmjopen-2018-022514 · Cited by 49
“12 The conservative attitude towards medication among Chinese parents likely explains why the prevalence of ADHD medication use among Hong Kong children is lower than that of other developed countries 13 and that the medication adherence rate was found to be low in a community sample of children with ADHD.”
InfluentialGroenman, A. P., Schweren, L. J. S., Weeda, W., Luman, M., Noordermeer, S. D. S., Heslenfeld, D. J., Franke, B., Faraone, S. V., Rommelse, N., Hartman, C. A., et al. (2019) · European Child & Adolescent Psychiatry · doi:10.1007/s00787-019-01283-y · Cited by 36
Self-citationGhirardi, L., Larsson, H., Chang, Z., Chen, Q., Quinn, P. D., Hur, K., Gibbons, R. D., & D’Onofrio, B. M. (2020) · Journal of the American Academy of Child & Adolescent Psychiatry · doi:10.1016/j.jaac.2019.06.010 · Cited by 35
Nagashima, M., Monden, Y., Dan, I., Dan, H., Mizutani, T., Tsuzuki, D., Kyutoku, Y., Gunji, Y., Hirano, D., Taniguchi, T., et al. (2014) · Neurophotonics · doi:10.1117/1.nph.1.2.025007 · Cited by 39
Molina, B. S. G., Kipp, H., Joseph, H. M., Engster, S. A., Harty, S. C., Dawkins, M., Lindstrom, R. A., Bauer, D. J., & Bangalore, S. S. (2019) · Academic Pediatrics · doi:10.1016/j.acap.2019.06.002 · Cited by 38
“Statistically significant decreases from baseline to post-intervention were found for three diversion risk factors: (1) number of times approached to divert, (2) intent to share, sell, or trade stimulants, and (3) disclosure of stimulant use.”
BackgroundInsights into attention-deficit/hyperactivity disorder from recent genetic studies
Brikell, I., Burton, C. L., Mota, N. R., & Martin, J. (2021) · Psychological Medicine · doi:10.1017/s0033291721000982 · Cited by 42
“Stimulants are typically the first-line recommended drug treatment and have been shown to be effective in children and adults across several meta-analyses (Faraone & Buitelaar, 2010; Moriyama et al., 2013).”
BackgroundEffects of white noise on off-task behavior and academic responding for children with ADHD.
Cook, A., Bradley‐Johnson, S., & Johnson, C. M. (2014) · Journal of Applied Behavior Analysis · doi:10.1002/jaba.79 · Cited by 34
“Although stimulants have been found to be effective in reducing these symptoms (Faraone & Buitelaar, 2010) and increasing school performance (McInnes, Bedard, Hogg-Johnson, & Tannock, 2007), they can have side effects such as decreased appetite, insomnia, anxiety, and cardiovascular problems…”
BackgroundKollins, S. H., Schoenfelder, E. N., English, J. S., Holdaway, A., Van Voorhees, E., O’Brien, B. R., Dew, R., & Chrisman, A. K. (2015) · Journal of Substance Abuse Treatment · doi:10.1016/j.jsat.2014.07.014 · Cited by 34
“Although hundreds of studies have documented the efficacy of MPH for treating ADHD (Faraone, Biederman, & Roe, 2002; Faraone & Buitelaar, 2010; Faraone, Spencer, Aleardi, Pagano, & Biederman, 2004), significant increases in prescription rates of MPH over the last 15 years have led to controversy…”
BackgroundAchieving Remission as a Routine Goal of Pharmacotherapy in Attention-Deficit Hyperactivity Disorder
Ramos-Quiroga, J. A., & Casas, M. (2011) · CNS Drugs · doi:10.2165/11538450-000000000-00000 · Cited by 33
Adjei, A. L., Teuscher, N. S., Kupper, R. J., Chang, W.-W., Greenhill, L. L., Newcorn, J. H., Connor, D. F., & Wigal, S. B. (2014) · Journal of Child and Adolescent Psychopharmacology · doi:10.1089/cap.2013.0135 · Cited by 39
“The efficacy and safety of a number of MPH ER formulations compared with placebo have been demonstrated both individually and through meta-analyses (Banaschewski et al. 2006; Faraone et al. 2006; Faraone and Buitelaar 2010).”
Faraone, S. V. (2012) · Journal of Attention Disorders · doi:10.1177/1087054710379738 · Cited by 33
Self-citationIdrees, I., Bellato, A., Cortese, S., & Groom, M. J. (2022) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2022.104968 · Cited by 43
Bussing, R., Meyer, J. M., Zima, B. T., Mason, D. M., GARY, F. A., & GARVAN, C. W. (2015) · International Journal of Environmental Research and Public Health · doi:10.3390/ijerph120911893 · Cited by 36
“Attention-deficit/hyperactivity disorder (ADHD) is a chronic neurodevelopmental disorder with significant public health implications, because it is (1) common, affecting more than 1 in 20 children [1]; (2) associated with significant adverse outcomes for youth [2,3] and their family members [4]; and (3) treatable with…”
BackgroundCortese, S., D’Acunto, G., Konofal, É., Masi, G., & Vitiello, B. (2017) · CNS Drugs · doi:10.1007/s40263-017-0409-0 · Cited by 41
Methylphenidate alters selective attention by amplifying salience
ter Huurne, N., Fallon, S. J., van Schouwenburg, M., van der Schaaf, M., Buitelaar, J., Jensen, O., & Cools, R. (2015) · Psychopharmacology · doi:10.1007/s00213-015-4059-y · Cited by 31
“In addition, inattentive and hyperactivity/ impulsivity symptoms of ADHD were assessed with an ADHD DSM-IV self-report questionnaire (DuPaul and Anastopoulos 1998).”
Self-citationMacphee, F. L., Merrill, B. M., Altszuler, A. R., Ramos, M. C., Gnagy, E. M., Greiner, A. R., Coxe, S., Raiker, J. S., Coles, E., Burger, L., et al. (2019) · School Psychology Review · doi:10.17105/spr-2017-0151.v48-3 · Cited by 12
Psychostimulant prescribing trends in a paediatric population in Ireland: a national cohort study
Boland, F., Galvin, R., Reulbach, U., Motterlini, N., Kelly, D., Bennett, K., & Fahey, T. P. (2015) · BMC Pediatrics · doi:10.1186/s12887-015-0435-3 · Cited by 35
Background, clinical features and treatment of attention deficit hyperactivity disorder in children
Warikoo, N., & Faraone, S. V. (2013) · Expert Opinion on Pharmacotherapy · doi:10.1517/14656566.2013.818977 · Cited by 41
Self-citationBiederman, J., Fried, R. S., DiSalvo, M., Woodworth, K. Y., Biederman, I., Driscoll, H., Noyes, E. J., Faraone, S. V., & Perlis, R. H. (2020) · Psychopharmacology · doi:10.1007/s00213-020-05576-y · Cited by 37
“…safety and efficacy of stimulants (Spencer et al. 2005; Spencer et al. 2007; Spencer et al. 2013; Biederman et al. 2006a; Medori et al. 2008; Faraone and Glatt 2009; Canadian ADHD Resource Alliance 2008; Kendall et al. 2008; Kooij et al. 2010; Faraone and Glatt 2010; Faraone and Buitelaar 2010).”
BackgroundSelf-citationOmega-6 to Omega-3 Fatty Acid Ratio in Patients with ADHD: A Meta-Analysis.
LaChance, L., McKenzie, K. J., Taylor, V. H., & Vigod, S. N. (2016) · PubMed Central · Cited by 57
Schoeman, R., & Liebenberg, R. (2017) · South African Journal of Psychiatry · doi:10.4102/sajpsychiatry.v23i0.1060 · Cited by 53
Lisdexamfetamine Dimesylate: A New Therapeutic Option for Attention-Deficit Hyperactivity Disorder
Steer, C., Froelich, J., Soutullo, C. A., Johnson, M., & Shaw, M. (2012) · CNS Drugs · doi:10.2165/11634340-000000000-00000 · Cited by 30
“02).([50]) The number needed to treat (NNT) was lower for amfetamines (2.”
BackgroundAttention-deficit/hyperactivity disorder treatment: what are the long-term cardiovascular risks?
Hammerness, P. G., Karampahtsis, C., Babalola, R., & Alexander, M. E. (2015) · Expert Opinion on Drug Safety · doi:10.1517/14740338.2015.1011620 · Cited by 30
“Overall, the mean effect size of stimulants is large in adult and child ADHD populations [20,21].”
BackgroundGrünblatt, E., Bartl, J., & Walitza, S. (2018) · Translational Psychiatry · doi:10.1038/s41398-018-0096-8 · Cited by 37
Biederman, J., Fried, R. S., DiSalvo, M., Woodworth, K. Y., Biederman, I., Noyes, E. J., Faraone, S. V., & Perlis, R. H. (2019) · Journal of Clinical Psychopharmacology · doi:10.1097/jcp.0000000000001055 · Cited by 30
Self-citationNeurobiology of Attention Deficit Hyperactivity Disorder
Faraone, S. V., & Radonjić, N. V. (2023) · Springer eBooks · doi:10.1007/978-3-030-42825-9_33-1 · Cited by 35
Self-citationPharmacological treatment of attention-deficit/hyperactivity disorder: assessing outcomes
Adamo, N., Seth, S., & Coghill, D. (2015) · Expert Review of Clinical Pharmacology · doi:10.1586/17512433.2015.1050379 · Cited by 35
EEG theta and beta power spectra in adolescents with ADHD versus adolescents with ASD + ADHD
Bink, M., Boxtel, G. J. M. V., Popma, A., Bongers, I. L., Denissen, A. J. M., & van Nieuwenhuizen, C. (2014) · European Child & Adolescent Psychiatry · doi:10.1007/s00787-014-0632-x · Cited by 35
“Stimulant medication that seems effective for ADHD treatment [5] is also prescribed in cases of comorbid ASD and ADHD (ASD ? ADHD).”
BackgroundClinical Gains from Including Both Dextroamphetamine and Methylphenidate in Stimulant Trials
Ramtvedt, B. E., Røinås, E., Aabech, H. S., & Sundet, K. S. (2013) · Journal of Child and Adolescent Psychopharmacology · doi:10.1089/cap.2012.0085 · Cited by 30
“…in children and adolescents found the effect size of amphetamine products to be moderately but significantly greater than that of methylphenidate, although the authors noted that comparisons among stimulants are hindered by the absence of direct comparative trials (Faraone and Buitelaar 2010).”
BackgroundResultLarrañaga-Fragoso, P., Noval, S., Rivero, J. C., & Bueis, A. B. D. L. (2015) · Journal of American Association for Pediatric Ophthalmology and Strabismus · doi:10.1016/j.jaapos.2015.04.005 · Cited by 33
Fostick, L. (2017) · Journal of Speech Language and Hearing Research · doi:10.1044/2017_jslhr-h-16-0074 · Cited by 32
Driving among Adolescents with Autism Spectrum Disorder and Attention-Deficit Hyperactivity Disorder
Bishop, H. J., Boe, L., Stavrinos, D., & Mirman, J. H. (2018) · Safety · doi:10.3390/safety4030040 · Cited by 29
“, inattention, hyperactivity and impulsivity), and can improve adaptive abilities of adolescents with ADHD [82], which includes complex skills such as driving.”
BackgroundAttention-Deficit/Hyperactivity Disorder in Children and Adolescents
Carbray, J. A. (2018) · Journal of Psychosocial Nursing and Mental Health Services · doi:10.3928/02793695-20181112-02 · Cited by 31
Vertessen, K., Luman, M., Staff, A., Bet, P., de Vries, R., Twisk, J., & Oosterlaan, J. (2022) · Journal of the American Academy of Child & Adolescent Psychiatry · doi:10.1016/j.jaac.2021.08.023 · Cited by 29
Mick, E. O., McGough, J. J., Middleton, F. A., Neale, B. M., & Faraone, S. V. (2010) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2010.11.037 · Cited by 34
Self-citationVollebregt, M. A., van Dongen‐Boomsma, M., Slaats-Willemse, D. I. E., & Buitelaar, J. K. (2014) · Frontiers in Human Neuroscience · doi:10.3389/fnhum.2014.00321 · Cited by 30
“While medication is the most effective treatment in ADHD (Faraone and Buitelaar, 2010), it also entails a number of concerns.”
Self-citationMeta-Analysis and Moderator Analysis: Can the Field Develop Further?
Bloch, M. H. (2014) · Journal of the American Academy of Child & Adolescent Psychiatry · doi:10.1016/j.jaac.2013.12.001 · Cited by 28
Complexities for Assessment and Treatment of Co-Occurring ADHD and Tics
Coffey, B. J. (2015) · Current Developmental Disorders Reports · doi:10.1007/s40474-015-0061-7 · Cited by 30
Pharmacological treatment of cognitive deficits in nondementing mental health disorders
Robbins, T. W. (2019) · Dialogues in Clinical Neuroscience · doi:10.31887/dcns.2019.21.3/trobbins · Cited by 33
Grünblatt, E., Homolak, J., Perhoč, A. B., Virag, D., Knezović, A., Barilar, J. O., Riederer, P., Walitza, S., Tackenberg, C., & Šalković‐Petrišić, M. (2023) · Frontiers in Neuroscience · doi:10.3389/fnins.2023.1104985 · Cited by 29
Bink, M., Bongers, I. L., Popma, A., Janssen, T. W. P., & van Nieuwenhuizen, C. (2016) · BJPsych Open · doi:10.1192/bjpo.bp.115.000166 · Cited by 30
Faraone, S. V., Hess, J., & Wilens, T. (2019) · Journal of Attention Disorders · doi:10.1177/1087054719843182 · Cited by 27
Self-citationJain, R., Babcock, T., Burtea, T., Dirks, B., Adeyi, B., Scheckner, B., & Lasser, R. (2011) · Child and Adolescent Psychiatry and Mental Health · doi:10.1186/1753-2000-5-35 · Cited by 26
“Although both are considered efficacious, a meta-analysis of 23 studies comparing the efficacy of immediate-release (IR) formulations of MPH and amphetamine in the treatment of children with ADHD revealed small but statistically significant differences in favor of amphetamine [10].”
BackgroundEffects of atomoxetine on locomotor activity and impulsivity in the spontaneously hypertensive rat
Turner, M., Wilding, E., Cassidy, E., & Dommett, E. J. (2012) · Behavioural Brain Research · doi:10.1016/j.bbr.2012.12.025 · Cited by 27
Movement and nutrition in health and disease
Lange, K. W. (2017) · University of Regensburg Publication Server (University of Regensburg) · doi:10.5283/mnhd.2 · Cited by 35
Taylor, L. E., & Antshel, K. M. (2019) · Journal of Attention Disorders · doi:10.1177/1087054718821734 · Cited by 30
Janssen, T. W. P., Geladé, K., Bink, M., van Mourik, R., Twisk, J. W. R., Maras, A., & Oosterlaan, J. (2020) · Clinical Neurophysiology · doi:10.1016/j.clinph.2020.02.020 · Cited by 30
Gilmore, D., Longo, A., Krantz, M., Radford, D., & Hand, B. N. (2022) · Current Psychiatry Reports · doi:10.1007/s11920-022-01362-z · Cited by 35
Neural and Behavioral Endophenotypes in ADHD
del Campo, N., Müller, U., & Sahakian, B. J. (2012) · Current topics in behavioral neurosciences · doi:10.1007/7854_2012_200 · Cited by 32
Kollins, S. H., English, J. S., Itchon-Ramos, N., Chrisman, A. K., Dew, R., O’Brien, B., & McClernon, F. J. (2014) · Journal of Attention Disorders · doi:10.1177/1087054712440320 · Cited by 25
“…are frontline treatments for ADHD in children, adolescents, and adults, and myriad studies have documented the efficacy and safety of these products for treating the core symptoms of ADHD, including inattention, impulsivity, and hyperactivity (Faraone & Buitelaar, 2010; Faraone & Glatt, 2010).”
Background
Metadata
- Authors
- Faraone, S. V., & Buitelaar, J.
- Affiliations
- SUNY Upstate Medical University (US)
- Radboud University Nijmegen (NL)
- Corresponding author
- Faraone, Stephen V.
- Venue
- European Child & Adolescent Psychiatry
- Published
- 2009-09-10
- Volume
- 19
- Issue
- 4
- Pages
- 353-364
- ISSN
- 1018-8827 (ISSN-L)
- 1435-165X
- OpenAlex
- W2099805984
- Cited by
- 485
- References
- 54
- Citations by year
- 2026: 17 · 2025: 18 · 2024: 14 · 2023: 20 · 2022: 22 · 2021: 21 · 2020: 35 · 2019: 36 · 2018: 29 · 2017: 31 · 2016: 42 · 2015: 53 · 2014: 47 · 2013: 40 · 2012: 26
- FWCI
- 11.76
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springer.com/tdm (tdm)
- Locations
- European Child & Adolescent Psychiatry (publishedVersion)
- PubMed (publishedVersion)
- Radboud Repository (Radboud University) (publishedVersion)
- Radboud Repository (Radboud University) (submittedVersion)
- Funders
- Pfizer
- Topics
- Health Sciences › Medicine › Psychiatry and Mental health › Attention Deficit Hyperactivity Disorder
- Social Sciences › Psychology › Developmental and Educational Psychology › Behavioral and Psychological Studies
- Health Sciences › Medicine › Pediatrics, Perinatology and Child Health › Pharmaceutical studies and practices
- Keywords
- attention deficit hyperactivity disorder, stimulant medication, methylphenidate, amphetamine, drug efficacy comparison, placebo effect, hyperactivity, inattention, impulsivity, children and adolescents, dopamine signaling
- MeSH terms
- Adolescent, Adult, Central Nervous System Stimulants, Attention Deficit Disorder with Hyperactivity, Humans, Treatment Outcome
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.